Carlsmed (CARL) Income Statement (2024 - 2026)
Income Statement report data from Mar 31, 2024 to Mar 31, 2026 for Carlsmed (CARL).
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Reported currency: USD
| Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | |
|---|---|---|---|---|---|---|---|---|---|
Revenue and COGS | |||||||||
Total Revenue | 16M (+6.26%) | 15M (+16.07%) | 13M (+8.20%) | 12M (+18.55%) | 10M (-29.68%) | 14M (+119.88%) | 6.59M (+8.39%) | 6.08M | - |
Cost Of Revenue | 3.69M (+3.65%) | 3.56M (+13.02%) | 3.15M (-1.87%) | 3.21M (+25.88%) | 2.55M (-33.07%) | 3.81M (+112.85%) | 1.79M (+17.76%) | 1.52M | - |
Costof Goods And Services Sold | 3.69M (+3.65%) | 3.56M (+13.02%) | 3.15M (-1.87%) | 3.21M (+25.88%) | 2.55M (-33.07%) | 3.81M (+112.85%) | 1.79M (+17.76%) | 1.52M | - |
Gross Profit | 12M (+7.06%) | 12M (+16.92%) | 9.93M (+11.95%) | 8.87M (+16.10%) | 7.64M (-28.53%) | 11M (+122.71%) | 4.80M (+5.26%) | 4.56M | - |
Operating Expenses | |||||||||
Research And Development | 5.18M (-1.52%) | 5.26M (+18.20%) | 4.45M (+6.97%) | 4.16M (+32.06%) | 3.15M (-49.76%) | 6.27M (+55.20%) | 4.04M (+1.00%) | 4.00M | - |
Selling General And Administrative | 6.23M (+28.45%) | 4.85M (-1.22%) | 4.91M (+47.01%) | 3.34M (-3.75%) | 3.47M (-22.37%) | 4.47M (+132.81%) | 1.92M (-4.48%) | 2.01M | - |
Operating Expenses | 22M (+3.68%) | 21M (+10.39%) | 19M (+23.36%) | 15M (+15.04%) | 13M (-35.49%) | 21M (+64.63%) | 13M (+15.63%) | 11M | - |
Depreciation And Amortization | 100K (+150.00%) | 40K (-60.00%) | 100K (0.00%) | 100K (+150.00%) | 40K (-71.43%) | 140K | - | - | - |
Operating Income | |||||||||
Operating Income | -9.28M (-0.43%) | -9.32M (+3.21%) | -9.03M (+38.92%) | -6.50M (+13.64%) | -5.72M (-42.97%) | -10.03M (+28.92%) | -7.78M (+23.10%) | -6.32M | - |
Ebit | -9.28M (-0.43%) | -9.32M (+3.21%) | -9.03M (+38.92%) | -6.50M (+13.64%) | -5.72M (+24.89%) | -4.58M (-41.13%) | -7.78M (+23.10%) | -6.32M (+15.96%) | -5.45M |
EBITDA | -9.18M (-1.08%) | -9.28M (+3.92%) | -8.93M (+39.53%) | -6.40M (+12.68%) | -5.68M (+9.86%) | -5.17M (-30.23%) | -7.41M (+24.54%) | -5.95M (+9.17%) | -5.45M |
Other Income / Expenses | |||||||||
Interest Income | 890K (-13.59%) | 1.03M (+8.42%) | 950K (+179.41%) | 340K (-10.53%) | 380K (-25.49%) | 510K (+30.77%) | 390K (-9.30%) | 430K | - |
Interest Expense | 310K (-6.06%) | 330K (-13.16%) | 380K (+5.56%) | 360K (0.00%) | 360K (-38.98%) | 590K (+47.50%) | 400K (+21.21%) | 330K | - |
Net Interest Income | 580K (-17.14%) | 700K (+22.81%) | 570K | -30.00K | 20K | -90.00K (+800.00%) | -10.00K | 100K | - |
Other Non Operating Income | 580K (-38.30%) | 940K (+84.31%) | 510K | -260.00K (+2500.00%) | -10.00K (-92.31%) | -130.00K (+225.00%) | -40.00K | 40K | - |
Net Income | |||||||||
Net Income From Continuing Operations | -8.70M (+1.05%) | -8.61M (+0.94%) | -8.53M (+26.00%) | -6.77M (+18.15%) | -5.73M (+21.40%) | -4.72M (-39.56%) | -7.81M (+24.36%) | -6.28M (+15.23%) | -5.45M |
Net Income | -8.70M (+1.05%) | -8.61M (+0.94%) | -8.53M (+26.00%) | -6.77M (+18.15%) | -5.73M (+21.40%) | -4.72M (-39.56%) | -7.81M (+24.36%) | -6.28M (+15.23%) | -5.45M |
Comprehensive Income Net Of Tax | -8.70M (-70.64%) | -29.63M (+247.36%) | -8.53M (+26.00%) | -6.77M (+18.15%) | -5.73M (-76.38%) | -24.26M (+210.63%) | -7.81M (+24.36%) | -6.28M | - |